Global atherectomy and thrombectomy devices market is expected to witness lucrative growth over the forecast period due to the increasing demand for minimally invasive devices, rising prevalence of chronic conditions, technological advancements, ease of usage, and increasing market entrants. The global rise in geriatric population, lifestyle-associated changes, and genetic disorders among the population base are resulting in atherosclerosis and thrombosis, providing growth potential to the market. Atherosclerosis and thrombosis are the peripheral vascular diseases that obstruct the arterial blood flow due to the accumulation of WBCs and RBCs respectively. Adoption of sophisticated technology such as the advent of laser & ultraviolet radiation, helicutters, recombinant tissue technology, and 3D Image generation is additionally expected to provide growth platform to the market. Moreover, benefits such as early recovery, minimal incisions, reduced bleeding & scarring, higher surgical restoration rate, low trauma, and post-operative complications are expected to propel the demand in the market.
The overall atherectomy and thrombectomy devices market is segmented on the basis of product and region. The atherectomy market is classified into excimer laser, excisional, rotational, directional, orbital and jetstream atherectomy. Orbital and directional atherectomy occupies the largest share of the atherectomy market due to minimally invasive treatment, faster blood flow restoration, reduced procedure time, and application in complex patient cases. For instance, Silver Hawk and Turbohawk systems are directional atherectomy devices, differing in size and efficiency, used in the treatment of large lesions. Laser atherectomy is expected to gain popularity owing to minimize damage to the tissues, higher success rate, reduced trauma, and the ability to treat complex lesions. The thrombectomy devices market is classified into rheolytic, aspiration, rotational, and ultrasound devices. Ultrasound thrombolytic devices are expected to gain substantial market share owing to greater exposure to the surgery site, precision, better penetration through the lesions, no usage of other thrombolytic agents, and reduced collateral damage.
Geographically, the atherectomy and thrombectomy devices market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA. North America held the largest share attributing to prominent factors such as increasing prevalence of cardiovascular diseases, high disposable income, advanced diagnosis system, frequent lifestyle associated changes and rising geriatric population. Additionally, government initiatives to create awareness and sophisticated infrastructure are strong contributors to the growth of this market over the forecast period. Asia-Pacific region is expected to be the fastest-growing market primarily attributing to factors such as increasing patient awareness, improving healthcare infrastructure, and rising disposable income.
The key vendors dominating this market space are, Covidien PLC, Boston Scientific Corp., Spectranetics Corp., Bayer AG, Cardiovascular Systems Inc., Argon Medical Devices, Spectranetics Corp., Getinge AB, Straub Medical AG, Vascular Solutions Inc., Zoll Medical Corp., Terumo Medical Corp., Uscom Ltd., St. Jude Medical Inc., Sorin Group USA Inc., Ventracor Ltd.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.